166 related articles for article (PubMed ID: 16454545)
1. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets.
Clarke A; Deeks JJ; Shakir SA
Drug Saf; 2006; 29(2):175-81. PubMed ID: 16454545
[TBL] [Abstract][Full Text] [Related]
2. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
3. Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification.
Onakpoya IJ; Heneghan CJ; Aronson JK
Drug Saf; 2017 May; 40(5):431-441. PubMed ID: 28238125
[TBL] [Abstract][Full Text] [Related]
4. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy.
Abraham J; Davis C
Soc Sci Med; 2005 Sep; 61(5):881-92. PubMed ID: 15955393
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1328-1337. PubMed ID: 28691251
[TBL] [Abstract][Full Text] [Related]
6. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
McNaughton R; Huet G; Shakir S
BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
[TBL] [Abstract][Full Text] [Related]
7. Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2015 Feb; 13():26. PubMed ID: 25651859
[TBL] [Abstract][Full Text] [Related]
8. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
9. Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Nov; 14(1):191. PubMed ID: 27894343
[TBL] [Abstract][Full Text] [Related]
10. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
Lane S; Lynn E; Shakir S
BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
[TBL] [Abstract][Full Text] [Related]
11. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
12. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.
Brown JP; Wing K; Evans SJ; Bhaskaran K; Smeeth L; Douglas IJ
BMJ Open; 2019 Oct; 9(10):e028133. PubMed ID: 31662354
[TBL] [Abstract][Full Text] [Related]
13. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis.
Onakpoya IJ; Heneghan CJ; Aronson JK
Crit Rev Toxicol; 2016 Jul; 46(6):477-89. PubMed ID: 26941185
[TBL] [Abstract][Full Text] [Related]
14. Responding rapidly to FDA drug withdrawals: design and application of a new approach for a consumer health website.
Embi PJ; Acharya P; McCuistion M; Kishman CP; Haag D; Marine S
J Med Internet Res; 2006 Sep; 8(3):e16. PubMed ID: 17032632
[TBL] [Abstract][Full Text] [Related]
15. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature.
Onakpoya IJ; Heneghan CJ; Aronson JK
BMC Med; 2016 Feb; 14():10. PubMed ID: 26843061
[TBL] [Abstract][Full Text] [Related]
16. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
17. Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?
Kraft WK; Waldman SA
Drug Saf; 2001; 24(9):637-43. PubMed ID: 11522118
[TBL] [Abstract][Full Text] [Related]
18. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance of herbal medicines : a UK perspective.
Barnes J
Drug Saf; 2003; 26(12):829-51. PubMed ID: 12959628
[TBL] [Abstract][Full Text] [Related]
20. Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review.
Onakpoya IJ; Heneghan CJ; Aronson JK
Expert Opin Drug Saf; 2018 Jan; 17(1):63-72. PubMed ID: 29076385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]